Biomea Fusion, (id:7782 BMEA)
6.44 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 8:45:12 AM)
Exchange closed, opens in 1 day
1.26 USD (1.26%)
0.31 USD (0.31%)
-42.09 USD (-42.09%)
-42.86 USD (-42.86%)
-37.90 USD (-37.90%)
-68.43 USD (-68.43%)
About Biomea Fusion,
Market Capitalization 233.38M
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
| Headquarters (address) |
900 Middlefield Road Redwood City 94063 CA United States |
| Phone | 650 980 9099 |
| Website | https://biomeafusion.com |
| Employees | 107 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | BMEA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.61 - 22.74 |
| Market Capitalization | 233.38M |
| P/E trailing | -1.87 |
| P/E forward | -1.94 |
| Price/Book | 3.07 |
| Beta | -0.427 |
| EPS | -4.01 |
| EPS United States (ID:6, base:3402) | 24.22 |